Unknown

Dataset Information

0

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.


ABSTRACT: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated.Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n ?=?58) were ?18 years with LDL-C ?7.8 mmol/L or LDL-C ?5.1 mmol/L plus CHD disease, on maximally tolerated lipid-lowering therapy that excluded apheresis. Weekly subcutaneous injections of mipomersen 200 mg (n ?=?39) or placebo (n ?=?19) were added to lipid-lowering therapy for 26 weeks.percent reduction in LDL-C from baseline to 2 weeks after the last dose of treatment. Mipomersen (n?=?27) reduced LDL-C by 36%, from a baseline of 7.2 mmol/L, for a mean absolute reduction of 2.6 mmol/L. Conversely, mean LDL-C increased 13% in placebo (n?=?18) from a baseline of 6.5 mmol/L (mipomersen vs placebo p<0.001). Mipomersen produced statistically significant (p<0.001) reductions in apolipoprotein B and lipoprotein(a), with no change in high-density lipoprotein cholesterol. Mild-to-moderate injection site reactions were the most frequently reported adverse events with mipomersen. Mild-to-moderate flu-like symptoms were reported more often with mipomersen. Alanine transaminase increase, aspartate transaminase increase, and hepatic steatosis occurred in 21%, 13% and 13% of mipomersen treated patients, respectively. Adverse events by category for the placebo and mipomersen groups respectively were: total adverse events, 16(84.2%), 39(100%); serious adverse events, 0(0%), 6(15.4%); discontinuations due to adverse events, 1(5.3%), 8(20.5%) and cardiac adverse events, 1(5.3%), 5(12.8%).Mipomersen significantly reduced LDL-C, apolipoprotein B, total cholesterol and non-HDL-cholesterol, and lipoprotein(a). Mounting evidence suggests it may be a potential pharmacologic option for lowering LDL-C in patients with severe hypercholesterolemia not adequately controlled using existing therapies. Future studies will explore alternative dosing schedules aimed at minimizing side effects.ClinicalTrials.gov NCT00794664.

SUBMITTER: McGowan MP 

PROVIDER: S-EPMC3496741 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.

McGowan Mary P MP   Tardif Jean-Claude JC   Ceska Richard R   Burgess Lesley J LJ   Soran Handrean H   Gouni-Berthold Ioanna I   Wagener Gilbert G   Chasan-Taber Scott S  

PloS one 20121113 11


<h4>Objectives</h4>Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated.<h4>Methods and results</h4>Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n  = 58) were ≥18 years with LDL-C ≥7.8 mmol  ...[more]

Similar Datasets

| S-EPMC4268487 | biostudies-literature
| S-EPMC3513909 | biostudies-other
| S-EPMC9683660 | biostudies-literature
| S-EPMC8468752 | biostudies-literature
| S-EPMC7153222 | biostudies-literature
| S-EPMC7653043 | biostudies-literature
| S-EPMC6947617 | biostudies-literature
| S-EPMC4190302 | biostudies-literature
| S-EPMC10586791 | biostudies-literature
| S-EPMC4430683 | biostudies-literature